News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Erman Akkus: Durable stable/partial response to atezo-beva in Hepatocellular Carcinoma
Photo from Erman Akkus/X
Aug 31, 2024, 17:17

Erman Akkus: Durable stable/partial response to atezo-beva in Hepatocellular Carcinoma

Erman Akkus, Medical Oncology Fellow at Ankara University Faculty of Medicine, shared on X:

“Durable stable/partial response to atezo-beva in Hepatocellular Carcinoma.

Significant proportion of HCC tumors become ghost tumors (radiologically persistent without viable tumor cells)

Durable: PR/SD >6 mo
IMbrave150
•CR, PR, SD: 8.9%, 22.1%, 44.2%
•77.8% of PRs and 28.5% SDs were durable
•Durable response -> better survival

Real-word, resection after atezo-beva
•pCR: 57.7% of PR tumors, 16.7% of SD tumors”

Erman Akkus

Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab

Authors: Ying-Chun Shen, Tsung-Hao Liu, Alan Nicholas, Akihiko Soyama, Chang-Tsu Yuan, Tse-Ching Chen, Susumu Eguchi, Tomoharu Yoshizumi, Shinji Itoh, Noriaki Nakamura, Hisashi Kosaka, Masaki Kaibori, Takamichi Ishii, Etsuro Hatano, Chikara Ogawa, Atsushi Naganuma, Satoru Kakizaki, Chih-Hsien Cheng, Po-Ting Lin, Yung-YehSu, Chien-Huai Chuang, Li-Chun Lu, Chi-Jung Wu, Hung-Wei Wang, Kun-Ming Rau, Chih-Hung Hsu, Shi-Ming Lin, Yi-Hsiang Huang, Sairy Hernandez, Richard S. Finn, Masatoshi Kudo, Ann-Lii Cheng
Erman Akkus

Source: Erman Akkus/X

For more posts by Erman Akkus, visit oncodaily.com
AkihikoSoyama Alan Nicholas Ann-Lii Cheng Atsushi Naganuma cancer Chang-Tsu Yuan Chi-Jung Wu Chien-Huai Chuang Chih-Hsien Cheng Chih-Hung Hsu Chikara Ogawa Erman Akkus Etsuro Hatano Hepatocellular carcinoma (HCC) Hisashi Kosaka Hung-Wei Wang Kun-Ming Rau Li-Chun Lu Masaki Kaibori Masatoshi Kudo NoriakiNakamura OncoDaily Oncology Po-Ting Lin Richard S. Finn Sairy Hernandez Satoru Kakizaki Shi-Ming Lin Shinji Itoh SusumuEguchi Takamichi Ishii Tomoharu Yoshizumi Tse-Ching Chen Tsung-Hao Liu Yi-Hsiang Huang Ying-Chun Shen Yung-YehSu
Special Coverage
Blog
Dec 21, 2024, 11:30
Kyaw Thein: Tissue-Agnostic Drug Development in Cancer
Dialogues
Dec 21, 2024, 11:29
Beyond the Cancer Diagnosis: Dialogue with Marianne Arab, Hosted by Adrian Pogacian
Blog
Dec 21, 2024, 11:27
Aleix Prat: Carlos Fernandez de Larrea has been appointed as a Professor at the University of Barcelona
Blog
Dec 21, 2024, 11:25
Canadian Cancer Society - Natalie Wild's caregiver story
Blog
Dec 21, 2024, 11:24
Christy Brown: How many things can you dread more than 'your child has aggressive brain cancer?'
Blog
Dec 21, 2024, 11:18
Jose Fernando Moura: Pivotal SABCS24 summary hosted by Cancer Network
Blog
Dec 21, 2024, 11:18
Jérôme Salomon: President Macron, WHO Director-General and global health leaders inaugurate WHO Academy
Blog
Dec 21, 2024, 11:17
ChatGPT-Like AI Tool Promises to Speed Treatment Advances and Free Doctors’ Time by Matching Patients with Clinical Trials
Blog
Dec 21, 2024, 11:14
Mediamedic - Wenbin Zhou on Pyrotinib-based regimen in HER2-positive breast cancer
Blog
Dec 21, 2024, 11:12
Didier Verhoeven: Comparing survival in breast cancer in Belgian Breast Centres
Blog
Dec 21, 2024, 11:06
Every great journey has its finale - eCAN Joint Action
Drugs
Dec 21, 2024, 10:38
Hanna Foster: Market cap and Revenue of Cancer NGS Drugs providers in 2024